Sec Form 4 Filing - Coulie Bernard @ PLIANT THERAPEUTICS, INC. - 2020-06-05

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Coulie Bernard 2. Issuer Name and Ticker or Trading Symbol PLIANT THERAPEUTICS, INC. [ PLRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 06/05/2020 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/30/2020 M 613 ( 1 ) A $ 6.22 ( 1 ) 613 ( 1 ) D Common Stock 04/30/2020 M 48,227 ( 1 ) A $ 2.08 ( 1 ) 48,840 ( 1 ) D Common Stock 06/05/2020 C 25,397 A 474,317 I See footnote ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 6.22 ( 1 ) 03/31/2020 A 377,336 ( 1 ) ( 4 ) 03/30/2030 Common Stock 377,336 ( 1 ) $ 0 377,336 ( 1 ) D Stock Option (right to buy) $ 6.22 ( 1 ) 04/30/2020 M 613 ( 1 ) ( 4 ) 03/30/2030 Common Stock 613 ( 1 ) $ 0 376,723 ( 1 ) D Stock Option (right to buy) $ 2.08 ( 1 ) 04/30/2020 M 48,227 ( 1 ) ( 5 ) 01/23/2029 Common Stock 48,227 ( 1 ) $ 0 343,380 ( 1 ) D Series B Preferred Stock ( 2 ) 06/05/2020 C 181,594 ( 2 ) ( 2 ) Common Stock 25,397 $ 0 0 I See footnote ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Coulie Bernard C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO, CA94080 X President and CEO Signatures /s/ Anthony Franks, attorney-in-fact 06/09/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. ( 2 )The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. ( 3 )The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 4 )1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. ( 5 )1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.